Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib combined with TACE for unresectable early- and intermediate-stage hepatocellular carcinoma
ChiCTR2200057124Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Beijing YouAn Hospital. Primary endpoint: Progression-Free Survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200057124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057124.